{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:18Z","timestamp":1787260998822,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["5T32HL007604"],"award-info":[{"award-number":["5T32HL007604"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ahj.2026.107520","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:35:28Z","timestamp":1782228928000},"page":"107520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DOAC score among patients receiving Vitamin K antagonists"],"prefix":"10.1016","volume":"301","author":[{"given":"Rahul","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Palazzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionn Cl\u00e9irigh","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Hijazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Virdone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zimetbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick A.","family":"Secemsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107520_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107520_bib0002","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107520_bib0003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107520_bib0004","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107520_bib0005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107520_bib0006","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107520_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2026.107520_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023907","article-title":"Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA-AF Phase III registry","volume":"11","author":"Bayer","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107520_bib0009","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2018.11.024","article-title":"Use of direct oral anticoagulants among patients with limited income and resources","volume":"73","author":"Ting","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107520_bib0010","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1055\/a-2080-6171","article-title":"Geographical variation in the use of oral anticoagulation and clinical outcomes among patients with atrial fibrillation in Denmark, Sweden, and Finland","volume":"7","author":"Frost","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.ahj.2026.107520_bib0011","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ahj.2026.107520_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6707985","article-title":"Time trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States","volume":"2022","author":"Vora","year":"2022","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ahj.2026.107520_bib0013","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/europace\/euab303","article-title":"Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis","volume":"24","author":"Grymonprez","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2026.107520_bib0014","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2026.107520_bib0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107520_bib0016","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107520_bib0017","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2026.107520_bib0018","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ahj.2020.12.002","volume":"233","author":"Carnicelli","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107520_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: global Anticoagulant Registry in the FIELD (GARFIELD)","volume":"163","author":"Kakkar","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107520_bib0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107520_bib0021","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2026.107520_bib0022","unstructured":"SAS Institute Inc. SAS [Internet]; 2026. Available from: www.SAS.com. [accessed 7 March 2026]."},{"key":"10.1016\/j.ahj.2026.107520_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009530","article-title":"Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with Rivaroxaban","volume":"9","author":"Kirchhof","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107520_bib0024","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.2012.5034","article-title":"Association of aspirin use with major bleeding in patients with and without diabetes","volume":"307","author":"De Berardis","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107520_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2022.100136","article-title":"Left atrial appendage occlusion: current advances and remaining challenges","volume":"1","author":"Alkhouli","year":"2022","journal-title":"JACC Adv"},{"key":"10.1016\/j.ahj.2026.107520_bib0026","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u2013Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2026.107520_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11683-2","article-title":"Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation","volume":"7","author":"Rivera-Caravaca","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ahj.2026.107520_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/srep24376","article-title":"Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores","volume":"6","author":"Proietti","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ahj.2026.107520_bib0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107520_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107520_bib0031","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107520_bib0032","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107520_bib0033","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10840-014-9930-y","article-title":"Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"40","author":"Caldeira","year":"2014","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.ahj.2026.107520_bib0034","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107520_bib0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtha.2025.09.032","article-title":"Evaluation of the updated ABC-AF-bleeding score 2.0 in patients with atrial fibrillation treated with a direct oral anticoagulant or warfarin","volume":"24","author":"Hijazi","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2026.107520_bib0036","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/STROKEAHA.122.041701","article-title":"A genomic risk score identifies individuals at high risk for intracerebral hemorrhage","volume":"54","author":"Myserlis","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2026.107520_bib0037","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/STROKEAHA.122.041764","article-title":"A genetic risk score improves risk stratification for anticoagulation-related intracerebral hemorrhage","volume":"54","author":"Mayerhofer","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2026.107520_bib0038","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1111\/jth.15498","article-title":"Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation","volume":"19","author":"Siegbahn","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2026.107520_bib0039","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1111\/jth.15525","article-title":"Improving prediction of anticoagulant-related major bleeding in atrial fibrillation: the search for new biomarkers","volume":"19","author":"Berg","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2026.107520_bib0040","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jacc.2024.07.023","article-title":"Heart failure risk assessment using biomarkers in patients with atrial fibrillation: analysis from COMBINE-AF","volume":"84","author":"Haller","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107520_bib0041","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jacc.2024.11.052","article-title":"Biomarker-based model for prediction of ischemic stroke in patients with atrial fibrillation","volume":"85","author":"Wallentin","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107520_bib0042","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jacc.2024.12.021","article-title":"Biomarker-based stroke risk assessment in atrial fibrillation: is the time ripe?","volume":"85","author":"McIntyre","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:23:20Z","timestamp":1787257400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326001821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"alternative-id":["S0002870326001821"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107520","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DOAC score among patients receiving Vitamin K antagonists","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107520"}}